![Thomas Gidoin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Gidoin
Financieel Directeur/CFO bij
OSE IMMUNOTHERAPEUTICS
Profiel
Thomas Gidoin is Chief Financial Officer & Deputy CEO at OSE Immunotherapeutics SA since 2026.
Formerly, Controller at Ipsen SA from 2008 to 2011, Vice President-Finance at DBV Technologies SA from 2012 to 2015, and Chief Financial Officer at Gensight Biologics SA from 2015 to 2024.
Education includes graduate degrees from Ecole Supérieure de Gestion et Finances and NEOMA Business School.
Actieve functies van Thomas Gidoin
| Bedrijven | Functie | Begin |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Financieel Directeur/CFO | 20-08-2025 |
Eerdere bekende functies van Thomas Gidoin
| Bedrijven | Functie | Einde |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Financieel Directeur/CFO | 26-01-2024 |
| DBV TECHNOLOGIES | Financieel Directeur/CFO | 01-01-2015 |
| IPSEN | Comptroller/Controller/Auditor | 01-01-2011 |
Opleiding van Thomas Gidoin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
63
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Ecole Supérieure de Gestion et Finances
 Ecole Supérieure de Gestion et Finances Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
NEOMA Business School
 NEOMA Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
